Our focused drug screen included over 60 agents with potential activity for EPS. The agents were tested against a panel of EPS cell lines as well as normal (non-cancerous) cell lines. Multiple drug classes show promising activity for EPS, warranting more focused research. This chemical screen lays the foundation for selective agent testing so that we can correlate specific drug classes with identifiable markers associated with EPS and ultimately develop effective combination treatment strategies.
Thanks to pilot funding from personal EPS donors as well as the Sam Day Foundation, we were able to sequence multiple EPS cell lines and human tumor samples. Samples were processed for DNA and RNA sequencing in order to learn more about key mutations that may play a role in EPS. We have been working closely with our bioinformatics team at Omics Data Automation to thoroughly analyze the data. Significant findings will be presented in our upcoming manuscript. We likely need to sequence more patients’ tumors, which will require writing a new grant to cover the additional cost. Thus far, we are becoming increasingly interested in the tumor microenvironment of EPS as well as select, key pathways in the cell.
Through the CureFAST program at cc-TDI, we enrolled a new patient. The team at cc-TDI was able to create a primary cell culture from this donated tissue. This cell culture will be included in our chemical screening studies (results will be published in our upcoming manuscript). As a reminder, we are actively enrolling patients into our CuRe-FAST Program, whereby tumor samples can be donated to cc-TDI and used for research purposes, free of charge. Please contact Andy Woods ([email protected]) for more information and to enroll.